TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ISOPTO CARPINE

PILOCARPINE HYDROCHLORIDE
Oncology Approved 2010-06-22
1
Indication
--
Phase 3 Trials
1
Priority Reviews
15
Years on Market

Details

Status
Prescription
First Approved
2010-06-22
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: PILOCARPINE HYDROCHLORIDE

ISOPTO CARPINE Approval History

Loading approval history...

What ISOPTO CARPINE Treats

4 indications

ISOPTO CARPINE is approved for 4 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dry Mouth
  • Salivary Gland Hypofunction
  • Head and Neck Cancer
  • Sjogren's Syndrome
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ISOPTO CARPINE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

: Pilocarpine hydrochloride tablets, USP are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.